These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 26135549)

  • 1. Targeting α-synuclein as a therapeutic strategy for Parkinson's disease.
    Lawand NB; Saadé NE; El-Agnaf OM; Safieh-Garabedian B
    Expert Opin Ther Targets; 2015; 19(10):1351-60. PubMed ID: 26135549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy targeting α-synuclein, with relevance for future treatment of Parkinson's disease and other Lewy body disorders.
    Lindström V; Ihse E; Fagerqvist T; Bergström J; Nordström E; Möller C; Lannfelt L; Ingelsson M
    Immunotherapy; 2014; 6(2):141-53. PubMed ID: 24491088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
    Olanow CW; Brundin P
    Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New therapeutic approaches to target alpha-synuclein in Parkinson's disease: The role of immunotherapy.
    Fernández-Valle T; Gabilondo I; Gómez-Esteban JC
    Int Rev Neurobiol; 2019; 146():281-295. PubMed ID: 31349931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting intracellular and extracellular alpha-synuclein as a therapeutic strategy in Parkinson's disease and other synucleinopathies.
    Vekrellis K; Stefanis L
    Expert Opin Ther Targets; 2012 Apr; 16(4):421-32. PubMed ID: 22480256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beta-synuclein modulates alpha-synuclein neurotoxicity by reducing alpha-synuclein protein expression.
    Fan Y; Limprasert P; Murray IV; Smith AC; Lee VM; Trojanowski JQ; Sopher BL; La Spada AR
    Hum Mol Genet; 2006 Oct; 15(20):3002-11. PubMed ID: 16959793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The phosphorylation of α-synuclein: development and implication for the mechanism and therapy of the Parkinson's disease.
    Xu Y; Deng Y; Qing H
    J Neurochem; 2015 Oct; 135(1):4-18. PubMed ID: 26134497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease.
    Orimo S; Uchihara T; Nakamura A; Mori F; Kakita A; Wakabayashi K; Takahashi H
    Brain; 2008 Mar; 131(Pt 3):642-50. PubMed ID: 18079166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapeutic interventions in Parkinson's disease: Focus on α-Synuclein.
    Ganguly U; Singh S; Chakrabarti S; Saini AK; Saini RV
    Adv Protein Chem Struct Biol; 2022; 129():381-433. PubMed ID: 35305723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting alpha-synuclein for the treatment of Parkinson's disease.
    Rohn TT
    CNS Neurol Disord Drug Targets; 2012 Mar; 11(2):174-9. PubMed ID: 22483285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy in Parkinson's Disease: Micromanaging Alpha-Synuclein Aggregation.
    George S; Brundin P
    J Parkinsons Dis; 2015; 5(3):413-24. PubMed ID: 26406122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery.
    Lee VM; Trojanowski JQ
    Neuron; 2006 Oct; 52(1):33-8. PubMed ID: 17015225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-translational modification of α-synuclein in Parkinson's disease.
    Barrett PJ; Timothy Greenamyre J
    Brain Res; 2015 Dec; 1628(Pt B):247-253. PubMed ID: 26080075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigational α-synuclein aggregation inhibitors: hope for Parkinson's disease.
    Török N; Majláth Z; Szalárdy L; Vécsei L
    Expert Opin Investig Drugs; 2016 Nov; 25(11):1281-1294. PubMed ID: 27677932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High Throughput Sequencing Identifies MicroRNAs Mediating α-Synuclein Toxicity by Targeting Neuroactive-Ligand Receptor Interaction Pathway in Early Stage of Drosophila Parkinson's Disease Model.
    Kong Y; Liang X; Liu L; Zhang D; Wan C; Gan Z; Yuan L
    PLoS One; 2015; 10(9):e0137432. PubMed ID: 26361355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of novel conformation-selective α-synuclein antibodies as potential immunotherapeutic agents for Parkinson's disease.
    Henderson MX; Covell DJ; Chung CH; Pitkin RM; Sandler RM; Decker SC; Riddle DM; Zhang B; Gathagan RJ; James MJ; Trojanowski JQ; Brunden KR; Lee VMY; Luk KC
    Neurobiol Dis; 2020 Mar; 136():104712. PubMed ID: 31837422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting alpha-synuclein via the immune system in Parkinson's disease: Current vaccine therapies.
    Fleming SM; Davis A; Simons E
    Neuropharmacology; 2022 Jan; 202():108870. PubMed ID: 34742741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beyond α-synuclein transfer: pathology propagation in Parkinson's disease.
    Hansen C; Li JY
    Trends Mol Med; 2012 May; 18(5):248-55. PubMed ID: 22503115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. α-Synuclein synaptic pathology and its implications in the development of novel therapeutic approaches to cure Parkinson's disease.
    Bellucci A; Navarria L; Zaltieri M; Missale C; Spano P
    Brain Res; 2012 Jan; 1432():95-113. PubMed ID: 22153624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
    Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
    Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.